Pharmacological therapies used in COVID-19 treament. Bibliographical review
DOI:
https://doi.org/10.5377/rct.v13i25.10410Keywords:
SARS-CoV, MERS-CoV, SARS-CoV-2, pharmacological treatments, clinical trialsAbstract
In late 2019, an outbreak of a disease caused by a new coronavirus known internationally as COVID-19 emerged in China, spreading worldwide and declared a pandemic in March 2020. This virus causes respiratory diseases ranging from very slight to severe symptoms, which may cause the death of the patient. However, the marked increase in the understanding of the virus and the disease has allowed the development of diagnostic tests, current in-vitro trials and clinical trials of drugs, vaccines, and epidemiological control measures. In this article, we carry out a review of the information available in databases such as: Pubmed, MedlinePlus, EMBASE or Scopus, Cochrane Library, LILACS, Spanish Medical Index (IME), among others, until June of this year, to learn more about the pathogen, transmission, symptoms, diagnosis, pathogenesis and focusing on the pharmacological treatments mainly studied worldwide.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
© Journal Science and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
Share: copy and redistribute the material in any medium or format
Adapt: remix, transform, and build upon the material
Under the following conditions:
- Attribution: You must give appropriate credit to this work, provide a link to the license, and indicate whether changes were made. You may do so in any reasonable manner, but not in any way that suggests that the licensor endorses you or your use.
- NonCommercial use: You may not use the material for commercial purposes.
